Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies

Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models

Peregrine Pharmaceuticals Comments on Lawsuit

Peregrine Pharmaceuticals Completes Patient Enrollment in Bavituximab Combination Therapy Trial in Advanced Cancer Patients

Peregrine Pharmaceuticals Reports Financial Results for Third Quarter Fiscal Year 2007

Peregrine Pharmaceuticals to Announce Third Quarter FY 2007 Financial Results

Peregrine's Licensee Initiates Phase I Clinical Trial in Europe With Novel Tumor Necrosis Therapy Cancer Agent

Peregrine Pharmaceuticals Reports Positive Phase Ib Results for its Targeted Immunotherapy Bavituximab in Chronic Hepatitis C Infection